51
|
Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G, Bonfichi M, Pagnucco G, Salvaneschi L, Bernasconi C. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:607-12. [PMID: 10217192 DOI: 10.1038/sj.bmt.1701627] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF. Seven patients achieved CR or had normal hemopoietic reconstitution: two had an early relapse at days +53 and +48, two patients died from acute GVHD at days +31 and +96, one died of interstitial pneumonia at day +55, and two patients experienced long-term survival. One patient with refractory disease and nodal involvement who did not respond to the first BMT had overt expansion of the leukemia at day +36; one patient with Ph+ ALL and one with ANLL evolving from MDS, both with skin involvement, had blast cells in peripheral blood at day +27 and +26, respectively. Transient cytopenia occurred in all patients; a normal granulocyte and platelet count was achieved within 3 weeks in all patients but one; acute GVHD occurred in six patients, and four had chronic GVHD. This approach is feasible in patients in early relapse after allo-BMT. It assists prompt re-establishment of normal donor hematopoiesis avoiding the prolonged cytopenia observed after donor lymphocyte infusion in AL patients relapsed after allo-BMT.
Collapse
|
52
|
Alessiani M, Spada M, Bonfichi M, Ferrari P, Abbiati F, Arbustini E, Morbini P, Regazzi M, Iacona I, Noli S, Scandone M, Dionigi P, Zonta A. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. Transplant Proc 1998; 30:2577-8. [PMID: 9745496 DOI: 10.1016/s0041-1345(98)00735-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- M Alessiani
- Department of Surgery, Haematology, Pathology, Pharmacology, Anesthesiology, University of Pavia School of Medicine, I.R.C.C.S. San Matteo Hospital, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Spada M, Alessiani M, Bonfichi M, Viezzoli A, Pileggi A, Abbiati F, Alessandrino P, Bernasconi C, Dionigi P, Zonta A. Development of a model of combined bone marrow and small bowel transplantation in swine. Transplant Proc 1998; 30:2609-10. [PMID: 9745512 DOI: 10.1016/s0041-1345(98)00748-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- M Spada
- Department of Surgery, University of Pavia School of Medicine, I.R.C.C.S. San Matteo Hospital, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
54
|
Maiocchi MA, Nano R, Capelli E, Bonfichi M, Alessandrino EP, Bernasconi P. Serine protease detection in mixed lymphocyte cultures: a histochemical method for possible prediction of graft-versus-host disease. Haematologica 1998; 83:686-9. [PMID: 9793250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Graft-versus-host disease (GVHD) presents an important complication of allogeneic bone marrow transplantation. A method to predict GVHD might be the analysis of cytotoxic T lymphocyte precursors, but the technique requires the use of radioactive elements not suitable in all laboratories. DESIGN AND METHODS Serine esterase (SE) activity was studied by a cytochemical method in donor-recipient mixed lymphocytes cultures (MLC). Twelve patients, affected by acute or chronic leukemia, and 20 donors were studied. MLC incubated with and without growth factors (IGF-1 or IL-2), were analyzed. The relationship between positivity of MLC and GVHD in transplanted patients was evaluated. RESULTS The data obtained showed that the percentage of SE positive cells was higher in MLC compared to negative control MLC. The highest percentage of positive cells was found in the MLC obtained from unrelated subjects. INTERPRETATION AND CONCLUSIONS These results show that serine protease expression in MLC may be a predictive marker of GVHD and could be used as an additional early test associated with cytotoxicity.
Collapse
Affiliation(s)
- M A Maiocchi
- Dipartimento di Biologia Animale, Università di Pavia, Italy
| | | | | | | | | | | |
Collapse
|
55
|
Bernasconi C, Alessandrino EP, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A, Castelli G, Brusamolino E, Pagnucco G, Castagnola C. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102:678-83. [PMID: 9722293 DOI: 10.1046/j.1365-2141.1998.00816.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
One hundred and five consecutive primary high-risk myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia (sAML) evolving from MDS (performance status 0-3, ECOG) entered this study. Induction chemotherapy (CT) consisted of idarubicine 12 mg/m2 i.v. on days 1 and 2, etoposide 60 mg/m2/12h i.v. for 5d, Ara-C 120 mg/ m2/12h i.v. for 5d (one or two courses). Patients were randomized to receive or not G-CSF (5 microg/kg/d subcutaneously 48 h after the end of CT). 52 cases underwent CT alone and 53 CT+G-CSF. The CT+ G-CSF patients had a significantly shorter duration of neutropenia (8 nu 16d) with a lower incidence of infections and significantly better responses (CR+PR: 74% v 52%, P<0.05). 40 patients entered CR: 17 with CT and 2 3 with CT+G-CSF. Responders underwent two consolidation courses with the same CT, followed by high-dose Ara-C (2 g/m2 every 12h for 3 d). Most CRs were clonal. At present 21 responders have relapsed (median relapse-free survival 4 5 months). Eight responders received an allo-BMT, six are alive in CR 7-57 months post-transplant. Therefore allo-BMT only increases the chance of a long survival and possible cure. In conclusion, CT+G-CSF did not prolong either CR duration or survival; the growth factor support, however, increased the number of allo-transplantable cases by inducing higher remission rates and improving clinical conditions.
Collapse
Affiliation(s)
- C Bernasconi
- Istituto di Ematologia, Università di Pavia, IRCCS Policlinico San Matteo, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
56
|
Bonfichi M, Astori C, Alessandrino EP, Bernasconi P, Balduini A, Castagnola C, Brusamolino E, Pagnucco G, Canevari A, Trucco P, Bernasconi C. Growth factors in the therapy of myelodysplasia: biological aspects. Leuk Lymphoma 1997; 26 Suppl 1:35-40. [PMID: 9570678 DOI: 10.3109/10428199709058598] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.
Collapse
Affiliation(s)
- M Bonfichi
- Istituto di Ematologia, Università di Pavia-IRCCS Policlinico S. Matteo, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
57
|
Astori C, Bonfichi M, Pagnucco G, Bernasconi P, Lazzarino M, Orlandi E, Bernasconi C. Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. Br J Haematol 1997; 97:586-8. [PMID: 9207404 DOI: 10.1046/j.1365-2141.1997.912908.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We describe a 28-year-old man with paroxysmal nocturnal haemoglobinuria (PNH) and a high transfusion requirement. Prior to and during therapy with recombinant human erythropoietin (rHuEpo), we evaluated the levels of 'decay-accelerating-factor', CD55, and 'membrane-inhibitor-of-reactive-lysis', CD59, as markers of the disease, whilst CD58, a marker present on leucocytes, was utilized to monitor normal haemopoietic activity. The patient became transfusion independent 1 month after beginning rHuEpo and remains well. The analysis of CD55, CD59 and CD58 suggests that the efficacy of rHuEpo was due to a selective rHuEpo action on normal erythroid clones.
Collapse
Affiliation(s)
- C Astori
- Institute of Haematology, University of Pavia, I.R.C.C.S. Policlinico S. Matteo, Italy
| | | | | | | | | | | | | |
Collapse
|
58
|
Bernasconi C, Alessandrino E, Bernasconi P, Bonfichi M, Caldera D, Lazzarino M, Canevari A, Brusamolino E, Pagnucco G, Castagnola C. 161 G-CSF treatment after intensive chemotherapy in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: A randomized study. Leuk Res 1997. [DOI: 10.1016/s0145-2126(97)81405-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
59
|
Bernasconi P, Alessandrino EP, Caldera D, Bonfichi M, Boni M, Troletti D, Pagnucco G, Cavigliano P, Perotti C, Biaggi G. Intensive chemotherapy followed by donor PBSC in ANLL relapsed after allogeneic BMT. Bone Marrow Transplant 1995; 15:643-5. [PMID: 7655395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We describe a 42-year-old man with ANLL-M4 in relapse after allogeneic BMT, in whom a new CR was obtained by conventional chemotherapy followed by the infusion of his female donor PBSC. At the time of BMT he was in CR. Six months later a full hematological relapse occurred an a three drug 5-day regimen was started. Two days after the end of chemotherapy he received donor PBSC collected by two leukaphereses after mobilization with G-CSF, given subcutaneously at 5 micrograms/kg/day for 7 days. The mononuclear PBSC were 4.2 x 10(8)/kg; the CD34 positive cells were 8.2 x 10(6)/kg and the CFU-GM were 14 x 10(4)/kg. Two days after PBSC infusion the patient received G-CSF at a dose of 5 micrograms/kg/day. Hemopoietic recovery occurred promptly on day + 13 and Y-FISH revealed 14% of Y-spot positive cells in the marrow. On day +20 hematological and cytogenetic remission was documented. The percentage of recipient cells decreased from day +36 onwards following the occurrence of a grade II GVHD, from which the patient recovered 1 week later with oral cyclosporin A and intravenous high-dose steroids. At present (day +200 from relapse) the patient is still in CR with 3% of Y-spot positive cells.
Collapse
Affiliation(s)
- P Bernasconi
- Istituto di Ematologia, Università di Pavia, Divisione di Ematologia Policlinico S. Matteo IRCCS, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
60
|
Bernasconi P, Alessandrino EP, Boni M, Bonfichi M, Morra E, Lazzarino M, Campagnoli C, Astori C. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 1994; 46:270-7. [PMID: 8037176 DOI: 10.1002/ajh.2830460404] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
One hundred eighty-eight unselected consecutive patients with "de novo" myelodysplastic syndrome (MDS) were studied cytogenetically. They were subclassified as 4 refractory anemia with ringed sideroblasts (RARS), 67 refractory anemia (RA), 58 refractory anemia with excess of blasts (RAEB), 40 RAEB in transformation (RAEB-t), and 19 chronic myelomonocytic leukemia (CMML). The overall incidence of chromosome abnormalities was 69%. The RAEB and RAEB-t patients showed karyotypic changes, more often than RA and CMML (76% and 100% vs. 56% and 42%, respectively). The most frequent single anomaly was del(5)(q13-q22q33) (22 cases), followed by monosomy 7 or del 7q (11 cases), del(11) (q14q23) (8 cases), trisomy 8 (4 cases). Complex karyotypes (defined by the presence of three or more structural or numerical abnormalities) were detected in 33 patients. With regard to the FAB classification, del (5)(q13q33) was associated with RA, and complex rearrangements with RAEB and RAEB-t. Leukemic transformation occurred in 66 patients (46%), none with a normal karyotype or del(11)(q14q23) as single abnormality. In patients carrying 5q- alone, acute evolution correlated with proximal breakpoint localization, being found in no case with del(5)(q13q33) but in three out of four cases with del(5)(q22q33). Acute leukemia (AL) progression happened in all cases with complex rearrangements and monosomy 7 or del(7q). Two of the four trisomy eight patients evolved in AL. By using the Cox proportional hazard regression analysis it was demonstrated that the karyotype abnormality was a significant predictor of leukemic transformation (P < 0.001). Patients with abnormal karyotypes without complex abnormalities had a survival (median survival 12 months) shorter than that of cases with only normal metaphases (median 83 months) (P < 0.001); patients with a mixture of normal/abnormal metaphases had a median survival of 31 months. The median survival for complex karyotypes was 7 months. Among cases with single defects, del(5)(q13q33) showed the best survival (64 months), monosomy 7 and del(7q) the worst (7 months) (P < 0.001).
Collapse
Affiliation(s)
- P Bernasconi
- Division of Hematology, Policlinico San Matteo IRCCS, Pavia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
61
|
Martinetti M, Daielli C, Locatelli F, Prete L, Alessandrino E, Bonfichi M, Pastomerlo A, Salvaneschi L. Evidence for permissive and nonpermissive HLA molecular mismatching in MLC: Study in 39 pairs selected for unrelated bone marrow transplantation. Hum Immunol 1994. [DOI: 10.1016/0198-8859(94)90128-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
62
|
Bernasconi C, Lazzarino M, Canevari A, Morra E, Alessandrino E, Bernasconi P, Bonfichi M, Caldera D, Boni M, Troletti D. Intensive chemotherapy with or without G-CSF in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: Randomized clinical study. Leuk Res 1994. [DOI: 10.1016/0145-2126(94)90252-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
63
|
Domenegati E, Bonfichi M, Filisetti P, Reali F, Reposi C, Ciccone R. [Intravenous versus inhalation anesthetics in anesthesia for bone marrow harvest for transplantation]. Minerva Anestesiol 1993; 59:157-61. [PMID: 8327167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
It is well known that nitrous oxide and many volatile anaesthetic drugs possess a certain degree of myelodepressive activity. The authors' aim has been to evaluate the degree of proliferative activity after exposure to forane or propofol. Bone marrow samples have been cultured after general anaesthesia induced and maintained by the same agents; cultures have also been performed after samples exposure to forane and propofol. The results have not shown significative differences in the haemopoietic colonies growth of bone marrow harvested from patients underwent intravenous or inhalatory anaesthesia. In vitro study has shown a significative variation of the colonies growth at the forane higher concentration. Intravenous anaesthetic may be safer for bone marrow harvest for transplantation.
Collapse
Affiliation(s)
- E Domenegati
- I Servizio di Anestesia e Rianimazione, IRCCS Policlinico S. Matteo, Pavia
| | | | | | | | | | | |
Collapse
|
64
|
Lazzarino M, Morra E, Brusamolino E, Alessandrino EP, Orlandi E, Pagnucco G, Castagnola C, Bernasconi P, Merante S, Bonfichi M. Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea. Hematol Oncol 1991; 9:299-305. [PMID: 1748396 DOI: 10.1002/hon.2900090604] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We used intermediate doses of Ara-C (IDAra-C) in the treatment of 15 patients with chronic myelogenous leukemia (CML) in blast crisis and, combined with hydroxyurea, in 20 CML patients in accelerated phase. Patients with blastic CML received intensive 5-day courses of IDAra-C 600 mg/m2 every 12 h as a 2-h infusion. Of 15 patients, three achieved complete response (CR) and three partial response (PR), for an overall response rate of 40 per cent. All patients developed severe leukopenia and thrombocytopenia, and two died in hypoplasia. Except nausea and vomiting requiring medication, other nonhematologic toxicities were uncommon. Median response duration was 4 months (range 1 to 7 months). Survival was 5 months for responders and 1.5 months for nonresponders. Patients with CML in accelerated phase were treated with two-day courses of IDAra-C 600 mg/m2 every 12 h by 2-h infusion, every two-three weeks. Daily hydroxyurea 1-1.5 g/day was administered between courses. Of 20 patients, 15 (75 per cent) achieved a good PR with rapid improvement of the symptoms of disease acceleration. The median duration of response was 11 months (range 3 to 38 months); duration was over 24 months in five patients. The median survival from the start of IDAra-C was 13 months for responders and 3.5 months for nonresponders. We conclude that IDAra-C is an effective approach for CML in terminal phase. Its use in 5-day induction courses for blast crisis CML has a response rate comparable to that achieved with high-dose Ara-C. In patients in accelerated phase, the combination of short courses of IDAra-C with hydroxyurea is a well-tolerated treatment able to improve substantially the clinical and hematologic symptoms of disease progression.
Collapse
Affiliation(s)
- M Lazzarino
- Chair of Hematology, University of Pavia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
65
|
Morra E, Lazzarino M, Castello A, Inverardi D, Coci A, Alessandrino EP, Brusamolino E, Bernasconi P, Orlandi E, Bonfichi M. Risk assessment in myelodysplastic syndromes: value of clinical, hematologic and bone marrow histologic findings at presentation. Eur J Haematol 1990; 45:94-100. [PMID: 2209826 DOI: 10.1111/j.1600-0609.1990.tb00425.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We analyzed the prognostic value of clinical, hematologic and bone marrow (BM) histologic findings at presentation in 94 patients with myelodysplastic syndromes (MDS) (28 RA; 2 RARS; 34 RAEB; 6 CMML; 24 RAEB-t). With survival as the dependent variable, stepwise multivariate analysis indicated as the prognostically most important factors among the MDS taken as a whole: latency from the first symptoms to diagnosis, age, and percentage of BM blasts. In each main MDS group the most unfavorable initial characteristics were: 1) low Hb, no macro-megaloblastosis, male sex for RA/RARS; 2) low Hb and low platelet levels for RAEB/CMML; 3) granuloblastic hyperplasia and high BM blastosis for RAEB-t. Of the BM histologic parameters, only the percentage of blasts had significant prognostic value. Histologic assessment of BM blastosis, however, did not differ statistically from that based on cytologic examination of BM smears, so that marrow histology seemed not essential for initial prognostic assessment in MDS patients. The finding of abnormal localization of immature precursors (ALIP) in BM biopsies was associated with a negative trend without reaching statistical significance. Using four objective parameters of proven significance (age, Hb, platelets, and BM blasts) we devised a staging system of immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices.
Collapse
Affiliation(s)
- E Morra
- Division of Hematology, Istituto Scientifico Policlinico San Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
66
|
Alessandrino EP, Lazzarino M, Morra E, Bernasconi P, Colombo A, Bonfichi M, Caldera D, Bernasconi C. [Alpha-interferon and myelodysplastic syndromes]. Haematologica 1990; 75 Suppl 4:51-5. [PMID: 2074055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|
67
|
Orlandi E, Lazzarino M, Morra E, Castagnola C, Alessandrino EP, Bernasconi P, Bonfichi M, Bernasconi C. Impact of advanced age on the management of acute nonlymphocytic leukemia: a study of 103 patients. Acta Haematol 1990; 84:144-8. [PMID: 2123065 DOI: 10.1159/000205052] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Treatment and outcome of 103 consecutive patients aged greater than or equal to 60 with de novo acute nonlymphocytic leukemia (ANLL) were reviewed. Twenty-three cases (22%) were not suitable for induction chemotherapy because of very poor presenting general conditions and could receive supportive care alone. The majority of them died within 1 month. Twenty-eight patients (27%) aged greater than or equal to 70 and/or with concurrent nonhematologic disorders underwent mild induction chemotherapy, which produced 3 complete remissions. The median survival for this group was 2 months. Only 52 patients (50%) were considered eligible for conventional induction chemotherapy. For this group, response rate was 34.5%, the median survival was 3.5 months, and median survival for responding patients was 13 months. Only intensive chemotherapy seems capable of substantially improving prognosis for older ANLL patients. This approach, however, is feasible only in a minority of patients, due to a high incidence of life-threatening complications.
Collapse
Affiliation(s)
- E Orlandi
- Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
68
|
Caldera D, Alessandrino EP, Bernasconi P, Orlandi E, Bonfichi M, Boni M, Bernasconi C. Empiric antibiotic association in the management of febrile episodes in patients submitted to bone marrow transplantation. Bone Marrow Transplant 1989; 4 Suppl 4:160-3. [PMID: 2697431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- D Caldera
- Divisione di Ematologia, IRCCS, Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | |
Collapse
|
69
|
Lazzarino M, Morra E, Canevari A, Pagnucco G, Orlandi E, Bonfichi M, Bernasconi P, Inverardi D, Rondanelli R, Bernasconi C. Cyclosporine in the treatment of aplastic anaemia and pure red-cell aplasia. Bone Marrow Transplant 1989; 4 Suppl 4:165-7. [PMID: 2516753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- M Lazzarino
- Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
70
|
Bernasconi P, Alessandrino EP, Caldera D, Colombo A, Bonfichi M, Boni M, Castelli G, Lazzarino M, Bernasconi C. Cytogenetic analysis may improve BMT strategies in acute leukaemias. Bone Marrow Transplant 1989; 4 Suppl 4:73-6. [PMID: 2697442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- P Bernasconi
- Divisione di Ematologia, Policlinico San Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Alessandrino EP, Bernasconi P, Lazzarino M, Castelli G, Bonfichi M, Caldera D, Colombo A, Boni M, Bernasconi C. Cryopreservation of marrow cells for ABMT. Is there any effect on the harvested leukaemic cells? Bone Marrow Transplant 1989; 4 Suppl 4:81-4. [PMID: 2697444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- E P Alessandrino
- Division of Hematology, Policlinico S. Matteo IRCCS, Pavia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Lazzarino M, Morra E, Alessandrino EP, Orlandi E, Pagnucco G, Merante S, Bernasconi P, Inverardi D, Bonfichi M, Bernasconi C. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol Suppl 1989; 43:411-6. [PMID: 2612614 DOI: 10.1111/j.1600-0609.1989.tb00328.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
23 adult patients with refractory or relapsed acute myelogenous leukemia (AML) received salvage chemotherapy with mitoxantrone and etoposide. The regimen consisted of mitoxantrone, 10 mg/m2/d by 30-min infusion, and etoposide 100 mg/m2/d by 30-min infusion, given 12 h apart for 5 consecutive d. Of 23 patients treated, 13 met the criteria for highly refractory disease (6 primary resistant; 4 with early relapse during maintenance; 3 relapsed and refractory to reinduction). 10 patients had relapsed off-therapy more than 6 months after achieving first CR. Overall, 14 patients (61%) achieved a complete remission (CR): 6/13 (46%) with refractory AML, and 8/10 (80%) with relapsed AML. 2 patients had a partial remission, 2 died in aplasia, and 5 were nonresponders. In responding patients, the median time for recovery of granulocyte count was 27 d. The most important nonhematologic side effect was oral mucositis, which was severe in 35% of cases. No signs of cardiac toxicity were observed. The median CR duration was 5 months (range, 2 to 12+ months). The combination of mitoxantrone and etoposide appears a highly effective and relatively well tolerated salvage regimen for refractory and relapsed AML. Its incorporation into first-line induction and consolidation programs for newly diagnosed AML patients should be considered.
Collapse
Affiliation(s)
- M Lazzarino
- Division of Hematology, Istituto Scientifico Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
73
|
Castagnola C, Bonfichi M, Colombo A, Bernasconi P, Bernasconi C. Acute nonlymphocytic leukemia: evidence of clonogenic cells in peripheral blood in early complete remission. Acta Haematol 1989; 82:210-2. [PMID: 2511724 DOI: 10.1159/000205379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
We describe a patient with acute nonlymphocytic leukemia in whom chromosomal analysis showed a 8,21(q22;q22) translocation and who entered complete remission after one course of chemotherapy. During the post-chemotherapy aplastic phase blood-derived hemopoietic circulating stem cells were collected by continuous flow aphereses. Chromosomal analysis on the collected cells and on colonies (CFU-GM grown in agar) showed the same anomaly as was present at diagnosis in about 30% of those analyzed. This confirms the persistence of the malignant clone in the early phase of the clinical remission in acute nonlymphocytic leukemia.
Collapse
Affiliation(s)
- C Castagnola
- Division of Hematology, IRCCS Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | |
Collapse
|
74
|
Lazzarino M, Morra E, Alessandrino EP, Merante S, Bernasconi P, Bonfichi M, Caldera D, Bernasconi C. Treatment of relapsed and refractory acute myeloid leukemia in adults. Bone Marrow Transplant 1989; 4 Suppl 1:121-3. [PMID: 2653487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- M Lazzarino
- Division of Hematology, IRCCS Policlinico S. Matteo, Pavia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
75
|
Bernasconi P, Morra E, Lazzarino M, Alessandrino EP, Venelli S, Bonfichi M, Bernasconi C. Monosomy 7 in the blast crisis of Ph 1 positive chronic granulocytic leukaemia (CGL): incidence and clinico-haematological features. Br J Haematol 1987; 66:143-5. [PMID: 3474013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
76
|
Bernasconi P, Morra E, Lazzarind M, Alessandrino EP, Venelli S, Bonfichi M, Bernasconi C. MONOSOMY 7 IN THE BLAST CRISIS OF Ph 1POSITIVE CHRONIC GRANULOCYTIC LEUKAEMIA (CGL): INCIDENCE AND CLINICO-HAEMATOLOGICAL FEATURES. Br J Haematol 1987. [DOI: 10.1111/j.1365-2141.1987.00143.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
77
|
Gobbi PG, Cavalli C, Gendarini A, Bonfichi M, Galeone F, Inzoli A, Ascari E. Prognostic significance of serum albumin in Hodgkin's disease. Haematologica 1986; 71:95-102. [PMID: 3087839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
78
|
Carlo Stella C, Ghizzi A, Bonfichi M, Pedrazzoli P, Bobbio Pallavicini E, Gorini M. Cell- and humoral-mediated granulopoietic failure detected by CFU-GM assay in one case of Felty's syndrome unresponsive to prednisolone treatment. Haematologica 1985; 70:296-302. [PMID: 3935526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
79
|
Gobbi PG, Ricevuti G, Balduini C, Cavalli C, Gendarini A, Bonfichi M, Rizzo SC, Ascari E. Prognostic factors in non-Hodgkin's lymphomas. Acta Haematol 1985; 74:86-91. [PMID: 3937421 DOI: 10.1159/000206174] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Prognostic factors were investigated in 67 patients with non-Hodgkin's lymphomas, homogeneously staged and treated (COP or CHOP according to low or high malignant histotype). A large number of parameters were scrutinized in order to recognize those exhibiting a prognostic value regarding length of survival. All the parameters that singly appeared to influence survival were entered into a multiple regression factor analysis. The erythrocyte sedimentation rate (ESR), higher or lower than 35 mm at the 1st h, better discriminated the groups of patients surviving or not at a given time. The histologic type, according to the Kiel classification of malignancy, was the second best prognosticator when a short-term prediction was requested (survival or death after no more than 2.5 years), but showed insufficient statistical weight for predicting longer survivals (greater than 4 years). Stage seemed to be the third best prognosticator for the first years of survival, but only the second best for longer survivals. Other parameters had very low prognostic importance when compared with those above. The results were substantially confirmed by 28 other patients, taken as controls. The importance that such a simple and easy test as ESR may be adequate with regard to prognosis is emphasized.
Collapse
|
80
|
Ghizzi A, Carlo Stella C, Bonfichi M, Gorini M, Pedrazzoli P. [Biological screening of immuno-mediated marrow insufficiency by means of the CFU-GM assay]. Boll Soc Ital Biol Sper 1984; 60:2179-85. [PMID: 6525277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We studied in agar growth behaviour of bone marrow granulocyte-macrophage progenitor cells (CFU-GM) in 16 patients with marrow failure in order to discriminate patients with cells inhibiting granulopoiesis both in bone marrow and peripheral blood. Our experimental design was based on: a) agar culture of bone marrow cells before and after treatment with antilymphocyte globulin (AGL); b) agar co-culture of marrow cells with autologous lymphocytes from peripheral blood. ALG treatment of marrow cells determined CFU-GM growth increase in 4 out of 10 patients; in the same patients co-culture with autologous lymphocytes showed a significant inhibition of CFU-GM growth. The growth enhancement induced by ALG treatment "in vitro" associated with growth inhibition in the coculture suggests the existence of a lymphocyte population suppressing the granulopoiesis both in bone marrow and peripheral blood. With this work we propose an experimental model in order to discriminate marrow failure based on cell-mediated suppression of CFU-GM growth in patient susceptible of immunosuppressive therapy with ALG.
Collapse
|